We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Precigen Inc (PGEN) NPV

Sell:$1.59 Buy:$1.60 Change: $0.07 (4.22%)
NASDAQ:0.81%
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Sell:$1.59
Buy:$1.60
Change: $0.07 (4.22%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Sell:$1.59
Buy:$1.60
Change: $0.07 (4.22%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Contact details

Address:
20374 SENECA MEADOWS PARKWAY
GERMANTOWN
20876
United States
Telephone:
+1 (301) 5569900
Website:
https://precigen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PGEN
ISIN:
US74017N1054
Market cap:
$419.02 million
Shares in issue:
252.42 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Randal Kirk
    Executive Chairman of the Board
  • Helen Sabzevari
    President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
  • Harry Thomasian
    Chief Financial Officer
  • Rutul Shah
    Chief Operating Officer
  • Jeffrey Perez
    Senior Vice President - Intellectual Property Affairs
  • Donald Lehr
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.